Clinical Trials Browser

Phase 2 × belantamab mafodotin × 30 days × Clear all

NCT04876248 2026-03-31

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Phase 2 Active not recruiting

Multiple Myeloma

NCT04680468 2026-03-23

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Phase 2 Active not recruiting

Neoplasms, Plasma Cell